Award recognizes Rallybio as being among “the most promising private biotech startups”
FARMINGTON, Conn., October 2, 2018 – Rallybio, LLC, a development stage biotechnology company, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Rallybio was co-founded in January 2018 by Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA, recognized leaders from the biopharma industry. In April, the company announced that it had secured $37.0 million in Series A funding. Rallybio’s focus is on antibodies, small molecules and engineered proteins that have strong biological rationales for addressing specific disease mechanisms.
“We are very pleased to receive the Fierce 15 award as we look to develop highly innovative therapies to address the needs of patients with severe and rare disorders,” said Dr. Mackay. “Our ongoing commitment is to focus on transformative medical breakthroughs for patients who are currently suffering without effective treatment options.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16th annual Fierce 15 selection.
About FierceBiotech and the Fierce 15 Awards
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approvals, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Steve Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in a Series A funding led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, with additional public-sector participation from Connecticut Innovations. The Company is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program. For more information, please visit www.rallybio.com.
Jeffrey Fryer, CPA